and other interactions in phytomedicines

Chapter 7 Synergy and other interactions in phytomedicines




The term ‘synergy’ (or synergism, from the Greek syn-ergo, meaning working together) refers to the phenomenon where two or more agents act together to produce an effect greater than would have been predicted from a consideration of individual contributions. Synergy is generally assumed to play a part in the effects of phytomedicines, and the use of combinations of herbs is fundamental to the philosophy of Western medical herbalism, traditional Chinese medicine (TCM) and Ayurveda. This attitude to their formulation and use differentiates herbal products from conventional medicines, even those originally obtained from plants. Modern phytomedicines are usually found as whole or semipurified extracts and should, ideally, be standardized for their active constituents, where known, to ensure clinical reproducibility. The likelihood of synergistic interactions is also recognized in reports from the European Pharmacopoeia Commission, where the most common type of extract, exemplified by Hypericum perforatum, is described as having ‘constituents with known therapeutic or pharmacological activity which are not solely responsible for the overall clinical efficacy of the extract’. To complicate matters further, herbalists use preparations and mixtures that are not necessarily intended to target a particular organ, cell tissue or biochemical system. This kind of application has been described as the ‘herbal shotgun’ approach, as opposed to the ‘silver bullet’ method of conventional medicine, to distinguish the multitargeted approach of herbals from the single-target approach of synthetic drugs.



WHAT IS SYNERGY?


The term ‘synergy’ is now used very widely, and mainly inaccurately, to describe any kind of positive interaction between drugs. In pharmacology the term has a specific definition, but is often misapplied in practice. Whether an effect can truly be described as synergy, or is merely addition, is rarely established and evidence to prove it conclusively in herbal medicines is sparse. The opposite, antagonism, meaning ‘working against’, is a reduction in the overall expected effect. Put simply, both antagonism and synergism can be defined in relation to an additivity expectation, which can be calculated from the potency of individual mixture components. Synergism is an effect larger than additive, whereas antagonism is smaller than additive. There are two ways of calculating additivity expectations: dose addition and also independent action.


Interactions can also involve a potentiation of effects. The terms ‘synergism’, ‘additivity’ and ‘antagonism’ are applied to combinations where all components induce the effect of interest, whereas the term ‘potentiation’ should be applied where one or several ‘inactive’ compounds enhance or exacerbate the effect of other actives.


Synergy and other interactions can take place between the constituents of a single extract as well as in a mixture of herbs. Medical herbalists have always insisted that better results are obtained with whole plant extracts and combinations of these rather than with isolated compounds. TCM, in particular, uses complicated recipes and it has sometimes been thought that the inclusion of some herbs was unnecessary, but the rationale for such combinations is gaining increasing acceptance. A TCM herbal treatment for eczema was the subject of a clinical trial of 37 young patients (M. P. Sheehan and J. D. Atherton, Br. J. Dermatol., 1992, 126: 179–184), and investigations were carried out to identify the ‘active constituent(s)’ of the mixture. However, a programme of pharmacological tests failed to find a single active herb or compound: it was the herbal mixture that was so effective (J. D. Phillipson, reported in European Phytotelegram, 1994, 6: 33–40).



MEASURING SYNERGY


Although the idea of synergy is easy to understand, the measurement of it is more problematic. It is fairly straightforward to identify synergy when one of the agents is inactive and a combination of this with an active agent produces an effect greater than that observed for the active alone (although this is more correctly termed potentiation), but difficulties in measurement arise when more than one (and there might easily be several) are active. Various methods for calculation have been devised over the years, but the following are now thought to be the most useful:



PREDICTION OF EFFECTS


Synergy is deemed present if the total effect of a combination is greater than would be predicted on the basis of expected additive effects of the mixture. Such additivity expectations can be derived from dose addition or independent action. Often, anticipated additivity is calculated by simply adding up the effects of individual mixture components, but this method can produce paradoxical and erroneous results and is therefore deemed unreliable (A. Kortenkamp and R. Altenburger, 1998; see legend for Fig. 7.1). The opposite applies for antagonism, which is observed less than would have been predicted.


image

Fig. 7.1 An analysis of combination effects using the isobole method. A, Hypothetical dose–response curves for compounds A and B, and an equimolar mixture of A+B. An effect of 50 is produced by 10 (arbitrary) dose units of A or 100 dose units of B. The combination A+B yields this effect at 5 dose units (2.5 dose units A, 2.5 dose units B). Note that the curves for the individual compounds are dissimilar. B, Diagram showing isoboles for effect level ‘50’ derived from Fig. 7.1A. The solid line (additivity isobole) joining 10 dose units on the A axis and 100 dose units on the B axis describes combinations of A and B that are expected to yield an effect level of ‘50’, if the interaction between A and B is additive. For example, this should be the case with 7.5 dose units A plus 25 dose units B (point 1 on the additivity line), 5 dose units A plus 50 dose units B (point 2) or 2.5 dose units A plus 75 dose units B (point 3). However, the dose–response curves in Fig. 7.1A show that a combination of 2.5 dose units A and 2.5 dose units B is sufficient to produce this effect. Therefore a point below the additivity line is seen, yielding a concave-up isobole. It can be concluded that A and B interact with each other in a way that exacerbates their toxicity (synergism). Conversely, A and B antagonized each other if, e.g., 5 dose units of A plus 75 dose units of B were necessary to produce an effect level of 50 (open square 4). In this case, a point above the additivity line would appear, producing a concave-down isobole. C, Diagram showing isoboles for effect level ‘25’ derived from Fig. 7.1A


(From A. Kortenkamp and R. Altenburger 1998 Synergisms with mixtures of xenoestrogens: a re-evaluation using the methods of isoboles. Science of the Total Environment 221(1): 59–73, with permission.)



THE ISOBOLE METHOD


The isobole method is an application of dose addition. It is unequivocal proof of synergy because it is independent of any knowledge of mechanisms and applies under most conditions. It makes no assumptions about the behaviour of each agent and is applicable to multiple components of up to three constituents, so can be applied to the analysis of effects in herbal mixtures. The isobole method uses graphs constructed to show curves (isoboles) describing combinations of two compounds, A and B, which produce the same specified action – which can be any measurable effect (Fig. 7.1A,B). The axes of the graph (Fig. 7.1B) represent doses of the two compounds on a linear scale. A line joining the iso-effective doses A and B of the single agents predicts the combinations of A and B that will yield the same effect, provided the interaction between A and B is only additive. This is the ‘additivity line’, in which case, there is no interaction between the two agents and they could be considered to be behaving like dilutions of each other.


For additivity (zero interaction), the relationship can be expressed algebraically by the equation of Berenbaum (Pharmacol. Rev., 1989 41, 93–141; see Further reading):



image



However, if synergy occurs, then smaller amounts are needed to produce the effect (i.e. the effect of the combination exceeds expectation) and the equation becomes dA / DA + dB / DB < 1, and the isobole is said to be ‘concave-up’. The opposite applies for antagonism, and the equation becomes dA / DA + dB/DB > 1, producing a ‘concave-down’ isobole. It is actually possible to have synergy at a particular dose combination with antagonism at a different combination, and this would be reflected in the isobole. The position of isoboles varies depending on the effect level chosen for analysis (see Fig. 7.1B,C).


The isobole method can also be applied to mixtures in which only one of the two agents is active; in effect ‘potentiation’. In this case, the iso-effective dose of the agent lacking activity can be regarded as being infinitely large, so the additivity isobole runs parallel to the respective dose axis. Synergism will again yield a concave-up isobole and antagonism a concave-down isobole, as shown in Fig. 7.2.




DEMONSTRATING SYNERGY AND POLYVALENT ACTION IN PHYTOMEDICINES


Proving the existence of true synergistic interactions, even within a single herbal extract, is remarkably difficult, and explains why this crucial aspect of herbal medicines is not well documented. To do so requires the extract to be fractionated, tested, recombined and retested in various permutations to see how each is interacting with the others. To complicate matters further, herbalists normally use mixtures of extracts, many of which are traditional combinations that are not necessarily intended to target a single biochemical system or enzyme (S. Y. Mills and K. Bone, Principles and Practice of Phytotherapy, Churchill Livingstone, 2000), making evaluation of additive or synergistic effects even more difficult. Simple examples of this practice would be the inclusion of laxative herbs in products used for haemorrhoids, or choleretic herbs in digestive preparations. This is not synergy but a way of approaching treatment from several angles concurrently, and could be described as ‘polyvalent action’. This term is used to cover the various effects of multiple active constituents acting in combination, in harmony and possibly in synergy. It therefore overcomes some of the problems of defining the overall effect as synergistic even when it includes antagonism, if that applies to a reduction of undesirable effects. As a preliminary step in looking for synergistic interactions, it is possible to test the effect of individual extracts singly and in combination, which will give an indication of synergy or antagonism although no real evidence as to which compounds are interacting.


In conventional medicine it is now common practice to use several drugs to treat a single complaint, such as in hypertension, psychoses and especially cancer, and this approach applies even more to plant extracts, because combinations are already present within the plant. There might be other sound reasons for not isolating individual components in some herbs such as ginkgo, St John’s wort and ginseng, because these are traditionally used as standardized extracts for which there is positive clinical data. In some cases, the active ingredients may not even be fully known, and if synergy is involved, then bioassay-led fractionation (the usual method for identifying actives) would not even be possible (see P. Houghton, Phytother. Res., 2000, 14(6): 419–423). The identities of the main actives of many important herbs are still under discussion, and it would be unwise to exclude, by overpurification, any constituents that might contribute to efficacy. Even if the phytochemistry of a plant is well documented, the actual contribution of individual components to the overall effect might not have been ascertained. Examples include hawthorn (Crataegus oxycantha) as a cardiac tonic, hops (Humulus lupulus) as a sedative, black cohosh (Cimifuga racemosa) and chasteberry (Vitex agnus-castus) as hormone-balancing agents in women, saw palmetto (Serenoa repens) as an antiandrogen for prostatic hyperplasia, and devil’s claw (Harpagophytum procumbens) as an anti-inflammatory agent. In other cases, the actives are unstable, and attempts to remove them from the ‘protection’ of the herb or whole extract could render them inactive. Here the obvious examples are garlic (Allium sativum) and valerian (Valeriana spp.). Garlic is often formulated as a product containing the precursor alliin, and the enzyme alliinase, which in solution (i.e. in the stomach) liberates the active allicin and other unstable, but still active, decomposition products. This is not synergy but, effectively, a drug-delivery system.


Interactions in vivo might also occur between combinations that enhance or hinder therapeutic activity by affecting absorption, metabolism or excretion. Some of these can be seen in vitro, such as the complexing of plant polyphenols and tannins with many drugs, which could theoretically reduce their effectiveness. This does not seem to be a real problem, otherwise tea drinkers would find many of their prescribed medicines inactive. Other interactions will only be seen clinically, such as the effects of cytochrome P450 enzyme induction, which are only seen after a period of treatment.

< div class='tao-gold-member'>

Stay updated, free articles. Join our Telegram channel

Jul 18, 2016 | Posted by in PHARMACY | Comments Off on and other interactions in phytomedicines

Full access? Get Clinical Tree

Get Clinical Tree app for offline access